文献速递炎症性肠病

乌司奴单抗治疗英夫利西单抗难治性儿童溃疡性结肠炎的一年结局:多中心前瞻性研究

One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.
PubMed 文献 · Aliment Pharmacol Ther · 2021-04-28

该多中心前瞻性研究纳入25例抗TNF难治性儿童溃疡性结肠炎患者,接受静脉乌司奴单抗诱导后皮下维持治疗。第52周无激素临床缓解率为44%,仅抗TNF失败者缓解率69%,而既往 also 维多珠单抗失败者仅17%(P=0.008)。乌司奴单抗在此难治性儿童UC队列中显示有效,治疗失败与药物暴露不足无关。

要点

  • 儿童UC抗TNF失败后使用乌司奴单抗,52周无激素缓解率44%。
  • 仅抗TNF失败者缓解率69%,维多珠单抗也失败者仅17%(P=0.008)。
  • q4周给药谷浓度高于q8周,但更高暴露未带来更优缓解率。

核心结论

  • 乌司奴单抗在抗TNF难治性儿童溃疡性结肠炎中显示有效,第52周无激素临床缓解率为44%。
  • 既往也失败于维多珠单抗者缓解率显著低于仅抗TNF失败者(17% vs 69%,P=0.008)。
  • 治疗失败并非由于药物暴露不足。

研究设计与样本

  • 多中心前瞻性研究,纳入加拿大儿童IBD网络6个中心2018年1月至2019年11月启动乌司奴单抗的25例抗TNF难治性UC患儿。
  • 中位年龄14.8岁(IQR 12.3-16.2),72%为女性,UC病程2.3年(IQR 1.1-4.2)。
  • 静脉乌司奴单抗中位剂量/体重为6.4 mg/kg(IQR 5.5-7.5),第20周后测量谷浓度。
  • 主要终点为第52周皮下乌司奴单抗治疗下无激素临床缓解(PUCAI<10且≥4周无激素)。

主要发现

  • 意向治疗分析中,44%达到第52周无激素临床缓解。
  • 仅既往抗TNF失败者中9/13(69%)缓解,而 also 维多珠单抗失败者中2/12(17%)缓解(P=0.008)。
  • 11例缓解者中7例符合内镜改善标准(Mayo内镜子评分≤1或粪便钙卫蛋白<250 μg/g)。
  • q4周给药者谷浓度中位数8.7 μg/mL(IQR 4.6-9.9),q8周者为3.8 μg/mL(IQR 12.7-4.8),P=0.02,但更高暴露与更优临床缓解率无关。
  • 5例在静脉诱导后停用乌司奴单抗,其中4例接受结肠切除术;未观察到与治疗相关的不良事件。

关键数值与推荐

  • 无激素临床缓解定义:PUCAI<10且至少4周无激素。
  • 内镜改善定义:Mayo内镜子评分≤1,或未复查结肠镜者粪便钙卫蛋白<250 μg/g。
  • 第52周无激素缓解率:总体44%;仅抗TNF失败者69%; also 维多珠单抗失败者17%(P=0.008)。

临床怎么用

  • 对于抗TNF难治性儿童UC,乌司奴单抗可作为治疗选择,尤其适用于未暴露于维多珠单抗者。
  • 既往维多珠单抗失败者使用乌司奴单抗缓解率较低,需权衡治疗预期。
  • q4周给药谷浓度高于q8周,但更高暴露未显示更优缓解率,不支持仅基于浓度常规升级剂量。

局限性

  • 样本量小(25例),为前瞻性观察性研究,非随机对照。
  • 部分患者未复查结肠镜,内镜改善采用粪便钙卫蛋白替代定义。
  • 单臂设计,缺乏对照组,结果需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The phase 3 (UNIFI) trial of ustekinumab (anti-interleukin 12/23) demonstrated efficacy even after prior biologic failure in adult ulcerative colitis (UC), but paediatric data are lacking. AIM: To prospectively monitor efficacy and serum concentrations of ustekinumab given to children with UC refractory to other biologics. METHODS: Children with anti-TNF refractory UC initiating ustekinumab intravenously at sites of the Canadian Children IBD Network prior to 12/2019 are included. The primary endpoint was steroid-free clinical remission with subcutaneous ustekinumab at 52 weeks (Paediatric Ulcerative Colitis Activity Index <10, no steroids ≥4 weeks). Ustekinumab levels were measured after week 20. Endoscopic improvement was defined as Mayo endoscopic subscore ≤1, or faecal calprotectin (FCP) <250 μg/g if not re-colonoscoped. RESULTS: At six sites between 01/2018 and 11/2019, 25 children (median [IQR] age 14.8 years [12.3-16.2], 72% female) with UC duration 2.3 years (1.1-4.2) received intravenous ustekinumab (median dose/kg of 6.4 [5.5-7.5] mg). All patients had failed prior infliximab therapy, and 12 (48%) also vedolizumab. Five patients discontinued ustekinumab after IV induction (four undergoing colectomy). On intent to treat basis, 44% achieved the primary endpoint of steroid-free remission at week 52, including nine (69%) of 13 who previously treated with anti-TNF only vs two (17%) of 12 who previously failed also by vedolizumab (P = 0.008). Seven of 11 remitters met the criteria for endoscopic improvement. The median (IQR) trough levels (μg/mL) were greater with q4 vs q8 weekly dosing (8.7 [4.6-9.9] vs 3.8 [12.7-4.8]) P = 0.02, but greater exposure was not associated with a superior rate of clinical remission. No adverse events were associated with therapy. CONCLUSION: Ustekinumab demonstrated efficacy in this paediatric cohort with otherwise treatment-refractory UC. Treatment failure was not due to inadequate drug exposure.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Dhaliwal J, McKay HE, Deslandres C, et al. One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study. Aliment Pharmacol Ther. 2021. PMID: 33909911. doi:10.1111/apt.16388

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。